Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2002

View Archived Issues

SignalGene and Novuspharma enter collaboration and option agreement for SG-292

Novel prenyltranferase inhibitors useful in cancer therapy identified at Merck

New 5-HT6 antagonists for obesity and CNS disorders

Lilly presents novel glutamate receptor function enhancers

Protein kinase inhibitors in development at Morphochem

Nucleoside analogues and their use in viral infections and cancer

COX-2 inhibitors claimed by researchers at Temple University

CCR1 antagonists in early development at Pfizer

Isradipine safely reduces cocaine-related effects

Carrier-mediated active transport is responsible for hepatic uptake of Z-335

Alexion reviews third-quarter highlights

Positive phase III results announced for ophthalmic implant for diabetic macular edema

Roche Diagnostics acquires HPV patent portfolio from Institut Pasteur

GSK to evaluate BioVex's ImmunoVEX vaccine platform

ActivX and Kyorin enter drug discovery collaboration in type 2 diabetes

Clinical results for oral tridentate iron chelator ICL-670 discussed in Florence

Adenovirus-mediated ribonucleotide reductase gene therapy inhibits human colon cancer growth

TranzVector-mediated delivery of human IFNbeta gene effective in human tumor xenograft model

GVAX cancer vaccines highlighted at the ASGT meeting

Antiproliferative sulindac derivative targets the Ras pathway

New antimicrobial peptide may be useful for burn and wound infections

Adherex Technologies updates Exherin progress

Lexicon Genetics identifies new target for obesity drug development

Promising results reported for Trisenox in myelodysplastic syndromes

Transkaryotic Therapies broadens intellectual property in Gaucher's and Fabry's diseases

Wyeth discontinues development of PTP-112

Merck & Co. to refile Arcoxia NDA in second half of 2003

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...